CXCR4 and posterior cortical atrophy: Key findings of our study are: i) PCa TEC differ in cytological, junctional and functional properties from NEC; ii) TME mapping of treatment naïve PCa by scRNA-seq identified 27 subpopulations with distinct gene expression signatures; iii) novel PCa specific TEC markers were identified and orthogonally validated; iiii) we identified a prostate TEC specific artery EC gene signature associated with decreased survival; iv) CXCR4/CXCL12 axis is as novel promising anti-angiogenic target which was validated in vitro and in vivo.